Zika Update

Epidemic may be peaking and could end within three years, scientists suggest; dengue antibodies enhance risk of Zika infection; considering new strategies for the control of mosquito-borne disease outbreaks

Written byTanya Lewis
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Aedes aegyptiCDC, JAMES GATHANYThe Zika outbreak that has spurred a public health emergency throughout Central and South America may have peaked, according to an analysis by researchers at Imperial College London, U.K. Study coauthor Neil Ferguson and colleagues used available public health data to model the virus’s spread, finding that the epidemic is likely to burn itself out within three years as the population achieves herd immunity. It will likely be at least a decade before the next outbreak, the researchers reported today (July 14) in Science.

“If our projections are correct, cases will have dropped substantially by the end of next year, if not sooner,” Ferguson said in a statement. Traditional mosquito control efforts are unlikely to be successful, and could have the counterproductive effect of prolonging the epidemic, Ferguson and colleagues noted in their paper.

In a review published in the same journal, Ferguson and colleagues summarized the research on Zika to date, arguing there’s a need to get better at predicting infectious-disease outbreaks. “The rise of Zika after its long persistence as a disease of apparently little importance highlights how little we truly understand about the global spread of mosquito-borne viruses and other lesser known diseases,” study coauthor Justin Lessler, an epidemiologist at Johns Hopkins University in Baltimore, said ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies